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Summary  43 
Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system 44 
(CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We 45 
therefore investigated in children and adolescents with bone marrow (≥25% blasts) and/or CNS  46 
positive Burkitt lymphoma the chemoimmunotherapy combination of  rituximab (375mg/m2) and 47 
the standard chemotherapy arm of our previously reported French-American-British LMB 96 48 
trial. Central pathological and cytogenetic characterization was also performed. There were 40 49 
evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease ± 50 
leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade 51 
III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% 52 
and 26%, respectively. The 3 year event-free survival (EFS)/overall survival (OS) was 90% 53 
(95% CI, 76-96%) in the entire cohort and 93% (95% CI, 61-99%) in patients with CNS disease.    54 
Based on the results of this trial, an international randomized study of FAB/LMB 96 55 
chemotherapy ± rituximab for high risk patients is currently under investigation.  56 
Key words: children, adolescents, Burkitt Lymphoma, Burkitt Leukaemia, chemotherapy, 57 
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Introduction  59 
Approximately 1 in 4 children and adolescents with de-novo mature and Burkitt lymphoma (BL) 60 
present with high-risk disease that is either mature B-cell leukaemia (bone marrow ≥ 25% blasts 61 
[BM]) and/or have central nervous system (CNS) involvement. Both the Berlin-Frankfurt-62 
Münster (BFM) and French-American-British (FAB) international cooperative studies have 63 
unsuccessfully attempted to reduce the overall burden of chemotherapy in this high risk group of 64 
patients.  In the FAB 96 study, a randomized attempt to reduce the dose of cytarabine during 65 
consolidation and eliminate three final cycles of maintenance was halted early due to inferior 66 
event-free survival (EFS) (Cairo, et al 2012, Cairo, et al 2007) while the BFM 95 study 67 
concluded that reducing the infusion duration of methotrexate from 24 to 4 hours led to 68 
significantly inferior EFS in high risk (R3/R4) patients.(Woessmann, et al 2005) Subsets of 69 
children with BL, such as those with poor response to initial reduction, complex karyotypes, and 70 
those with combined BM and CNS disease, have a significantly worse prognosis (Cairo, et al 71 
2012, Cairo, et al 2007, Poirel, et al 2009) . 72 
 73 
Rituximab has been shown to improve EFS and overall survival (OS) when added to 74 
cyclophosphamide, adriamycin (oncovin, prednisone-(CHOP) based therapy in adults with 75 
diffuse large B-cell lymphoma (DLBCL) and also when combined with more aggressive therapy 76 
in adults with mature B-cell (Burkitt) lymphoma (BL) (Barnes, et al 2011, Coiffier, et al 2002, 77 
Corazzelli, et al 2012, Dunleavy, et al 2013, Pfreundschuh, et al 2006, Thomas, et al 2006). 78 
Unfortunately, all of these studies of rituximab and chemotherapy in adults with BL had few or 79 
no patients with BM and/or CNS involvement. Meinhardt et al. reported the safety and efficacy 80 
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de novo BL, including 19 evaluable patients with BM and/or CNS disease (Meinhardt, et al 82 
2010). We have previously reported the safety and efficacy of the combination of rituximab plus 83 
FAB/Lymphomes Malins B (LMB) 96 Group B chemotherapy in children with Stage III/IV 84 
DLBCL/BL (Goldman, et al 2013). However, to date there has been no prospective study 85 
investigating the combination of rituximab with FAB/LMB 96 Group C chemotherapy in 86 
children, adolescents or young adults with BL and CNS disease and/or BM involvement. 87 
Importantly, our previous study in children with BL and CNS disease only had a 75% 4 year EFS 88 
following standard systemic and intrathecal chemotherapy with FAB/LMB therapy (Cairo, et al 89 
2007). 90 
 91 
Patients and methods 92 
General 93 
The Children’s Oncology Group (COG) ANHL01P1 investigated the addition of rituximab to the 94 
FAB 96 C1 systemic and intrathecal chemotherapy backbone (Cairo, et al 2007). The trial was 95 
open to all COG centers in the United States, Canada, Australia and New Zealand. The protocol 96 
was approved at each respective institutional review board. Staging classification utilised the St. 97 
Jude Staging for NHL (Murphy 1980). Parents or patients over 18 years of age signed an 98 
institutional review board-approved informed consent before study enrollment in accordance 99 
with the Declaration of Helsinki. Safety reports and interim analyses were reviewed every 6 100 
months, then annually by the COG independent Data and Safety Monitoring Committee.  101 
 102 
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Patients under 30 years of age with newly diagnosed de-novo mature B-cell lymphoma classified 104 
as by World Health Organization criteria were eligible (Swerdlow, et al 2008). CD20 positive 105 
immunohistochemistry was required for study eligibility. Group C risk was defined as patients 106 
with BM ≥25% blasts and/or CNS disease (Cairo, et al 2007). CNS disease was defined as any 107 
cerebral spinal fluid (CSF) blasts found on diagnostic lumbar puncture and/or isolated 108 
intracerebral mass, cranial nerve palsy, clinical spinal cord compression and parameningeal 109 
extension as we have previously described (Cairo, et al 2007). Carriers of hepatitis B were 110 
eligible but carefully monitored for reactivation, as we have previously described (Goldman, et 111 
al 2013).  112 
 113 
Treatment 114 
Systemic and Intrathecal Chemotherapy. The systemic and intrathecal chemotherapy backbone 115 
for group C patients was similar to that reported in the FAB/LMB 96 study for the C1 arm 116 
(Cairo, et al 2007). The previous study (FAB/LMB 96) initially employed a 48-hour infusion of 117 
doxorubicin during the two induction cycles and the study was amended midway for 118 
unacceptable rates of grade III/IV mucositis and the anthracycline infusion was reduced to a 6 119 
hour infusion (Patte, et al 2007). The doxorubicin infusion was reduced to 30-60 minutes in the 120 
current COG ANHL01P1 group C trial. Non-alkaline hydration and one or more doses of 121 
rasburicase 0.2 mg/kg IV, generously supplied by Sanofi (Bridgewater, NJ), was administered to 122 
all patients at least 4 hours prior to initiating reduction therapy for prevention or treatment of 123 
tumour lysis syndrome. An initial reduction phase consisted of low-dose cyclophosphamide, 124 
Oncovin® (vincristine), and prednisone (COP). Induction courses consisted of COPADM1+2 125 
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prednisone, doxorubicin, high dose methotrexate [HDMTX] [8 gm/m2 in 4-hour infusion]), as 127 
we previously described (Cairo, et al 2007). Patients then received two identical consolidation 128 
courses, CYVE 1+2 (continuous infusion and high dose cytarabine and etoposide) (Fig 1). CNS 129 
negative patients received 10 prophylactic intrathecal injections while CNS positive 130 
patients received 13 intrathecal injections and an additional course of high dose 131 
methotrexate between CYVE consolidation cycles. A disease evaluation was performed after 132 
completion of consolidation cycles with any biopsy proven residual disease considered an event 133 
and patient removed from study. Patients without disease after consolidation received four 134 
maintenance courses as previously described (Fig 1) (Cairo, et al 2007). No patients received 135 
cranial irradiation, including those presenting with CNS disease. 136 
 137 
Immunotherapy. All rituximab infusions were administered at the standard dose of 375 mg/m2. 138 
Patients were pre-medicated with combination acetaminophen and diphenhydramine. Rituximab, 139 
generously supplied by Genentech (San Francisco, CA) through the Cancer Therapy Evaluation 140 
Program (CTEP), National Cancer Institute, was diluted in normal saline at a concentration of 1 141 
mg/ml. The monitoring and methods of administration of rituximab was identical to what we 142 
have previously described (Goldman, et al 2013). During induction cycles (COPADM), 143 
rituximab was administered 48 hours prior (day –2) and repeated on the day of chemotherapy 144 
administration (day 0). During consolidation cycles (CYVE), rituximab was administered just 145 
prior to chemotherapy administration (day 0). In the initial sub-pilot, the rituximab 146 
administration began with the second induction cycle (4 total doses) (Fig 1). The reason for 147 
initiating rituximab in the second induction cycle in the small initial cohort was to avoid 148 
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(rasburicase in reduction).  After the fourth sub-pilot patient was entered, the study was 150 
temporarily closed (~ 5 months) to accrual until all subpilot patients completed 151 
consolidation chemoimunotherapy and were evaluated for toxicity.  In the larger pilot study, 152 
rituximab was given beginning in the first induction cycle (6 total doses) (Fig 1). 153 
 154 
Pathology  155 
Central pathology review consisted of review of morphology, immunophenotype and genetic 156 
data from the original diagnostic biopsy. In addition, CD20 expression of the tumour was 157 
confirmed by immunohistochemistry. Four micron sections underwent immunoperoxidase 158 
staining for CD20 (L-26 clone, DAKO Cytomation, Carpinteria, CA) by standard methods 159 
following heat induced epitope retrieval in citrate buffer (pH6.0) on an automated stainer (ES, 160 
Ventana Medical Systems, Tucson, AZ). All steps were performed at 40°C. A case was scored as 161 
positive if >80% of the tumour cells stained for CD20.  162 
 163 
Cytogenetics and fluorescence in situ hybridization (FISH) analysis 164 
Cytogenetic analysis was performed, as we have previously described, with nomenclature 165 
according to the International System for Human Chromosome Nomenclature (2005) (Shaffer 166 
and Tommerup 2005) (Poirel, et al 2009). Interphase FISH analysis for MYC rearrangement was 167 
performed on a portion of the specimen submitted for cytogenetic analysis. A dual-color 168 
MYC/IGH translocation probe designed to detect t(8;14)(q24.1;q32) or a dual-color MYC break-169 
apart probe designed to detect rearrangements of the MYC gene region at 8q24.1 with various 170 
partner chromosomes was utilized according to the COG reference laboratories standard 171 
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solution and the nuclei were visualized and captured using a fluorescence microscope equipped 173 
with appropriate filters and imaging software.  174 
 175 
Statistics  176 
The objective of this study was to estimate the toxicity of and response rate to 177 
chemoimmunotherapy in Group C patients. Stevens-Johnson Syndrome (SJS), toxic epidermal 178 
necrosis (TEN) , the frequency of Grade ≥ 4 stomatitis (Grade ≥3 stomatitis for the pilot portion), 179 
delayed recovery beyond day +42 of the induction phase, and toxic deaths were considered 180 
events in the sub-pilot and pilot studies.  181 
 182 
Statistical considerations for the sub-pilot study for Group C patients.  183 
If a single toxic death occurred during the period from the second cycle of induction through the 184 
end of the second maintenance course among the 4 sub-pilot patients, the Study Committee 185 
would review the events and determine if the study would continue or if it would be modified or 186 
permanently stopped. 187 
 188 
Statistical considerations for assessing toxicity in the pilot.  189 
A 2-stage stopping rule was used to terminate this study if too many Group C patients 190 
experienced Grade ≥3 stomatitis during either cycle of COPADM + rituximab therapy 191 
(Induction). A rate greater than 70%, the observed rate in FAB LMB 96, was considered too 192 
high. The pilot study also monitored for the occurrence of SJS and toxic epidermal necrosis with 193 
any incidence of either during induction leading to temporary closure and review of the event. A 194 
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reduction phase until completion of second maintenance course of therapy. If any stopping rule 196 
was triggered, it was to be followed by a review by the Study Committee and COG Data and 197 
Safety Monitoring Committee.  198 
 199 
EFS was defined as the time from enrollment to the first occurrence of disease progression, 200 
relapse after response or death from any cause. OS was defined as the time from enrollment to 201 
death from any cause. Time to event for patients not experiencing an event was censored at their 202 
time of last follow-up. Estimates of the EFS and OS distributions were calculated using the 203 
Kaplan and Meier method. Ninety-five percent confidence intervals (CI95) for the Kaplan-Meier 204 
estimates of EFS and OS were calculated using standard errors according to Greenwood 205 
(Greenwood 1926).  206 
 207 
Results 208 
Patient demographics 209 
Four sub-pilot and forty-two pilot patients were enrolled, however, four pilot patients were 210 
determined to be ineligible (all prior to receiving rituximab) for the following reasons: 211 
chemotherapy started prior to enrollment (2 patients) and major informed consent deficiencies (2 212 
patients). In addition, 2 initially eligible patients were excluded for incorrect staging in one 213 
patient and parental withdrawal of consent prior to study therapy. Thus, 36 pilot and 4 sub-pilot 214 
patients were included in the final analysis making a total of 40 patients that were evaluated for 215 
the planned endpoints. The results of the pharmacokinetics of rituximab and the incidence and 216 
grade of tumour lysis syndrome (TLS) have been previously been reported in this patient 217 
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The mean age at study entry was 11 years (range 3-23). Eighty percent of patients were between 220 
4 and 15 years. The male to female ratio was 4:1. Sixty-three percent of patients had isolated BM 221 
involvement (≥25% blasts); 18% (7/40) had CNS disease with BL (< 25% BM blasts) and 222 
20% (8/40) had combined CNS and BM disease. Seventy-eight percent of patients had elevated 223 
lactate dehydrogenase ≥2 X upper institutional limit of normal at diagnosis (Table 1). 224 
 225 
Safety 226 
There were two toxic deaths among the 40 evaluable patients. The first death occurred in a 227 
teenager whom had been ill for several weeks prior to arrival at the COG center for therapy of 228 
Burkitt leukaemia. This patient died of pre-existing pulmonary aspergillosis soon after reduction 229 
therapy. The second death on study was secondary to grade V typhlitis and infection and 230 
occurred in a patient during the second induction cycle. The institutional investigator graded the 231 
typhlitis as probably related to rituximab. Although the study required leucovorin rescue and 232 
alkaline hydration until the serum methotrexate level was less than 0.1 micromol/L, the 233 
patient was discharged from the hospital with a methotrexate level of 0.12 micromol/L.  234 
This second toxic death triggered a prespecified study suspension.  Enhanced methotrexate 235 
guidelines as well added recommendations for aneorbic treatment of suspected typhlitis 236 
and mandatory notification of study chair of infectious complications were amended to the 237 
study.   After a ten month suspension, the study was reopened after approval of the data 238 
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Table 2 details the most common recurrent non-haematological grade III/IV toxicities by cycle 241 
of therapy with combined chemotherapy and rituximab. There were 54 reports in 13 patients 242 
(33%) of serious adverse events (SAE). Of these, only 1 SAE of grade 3 infusion reaction was 243 
definitely attributed to rituximab (total of 227 rituximab infusions). Of the remaining 53 SAE 244 
only 1 had a probable attribution to rituximab which was grade V typhlitis in the previously 245 
mentioned patient. The specified stopping rules for mucositis/stomatitis and SJS/TEN were not 246 
met during the conduct of the study. The focus on SJS/TEN was based on rare but highly 247 
morbid incidence reported in adult lymphoma and concern about combining with other 248 
skin and mucus membrane toxic agents such as high dose methotrexate (Foran, et al 2000). 249 
The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy 250 
and rituximab was 31% and 26% in COPADM1 and COPADM2, respectively. 251 
 252 
Haematopathology  253 
Adequate tissue for centrally reviewed histology was available in 73% (29/40) of patients 254 
enrolled. All of the patients had classical BL (World Health Organization) or Burkitt leukaemia 255 
(as defined by >25% BM involvement) (Swerdlow, et al 2008). The remaining 11 cases had 256 
classical BL by report of the local pathologist. CD20 was strongly and uniformly expressed on 257 
all centrally reviewed cases.  258 
 259 
FISH analysis 260 
Conventional cytogenetic studies were attempted on 36 cases, and resulted in abnormal findings 261 
in 26 (72%). Normal karyotypes were observed in 2 cases (5.5%), and 8 cases (22%) failed to 262 

















anuscript          




a MYC rearrangement. The various MYC rearrangements detected included, a t(2;8)(p11.2;q24.1) 264 
in 1/25 cases (4%), a t(8;22)(q24.1;q11.2) in 3/25 cases (12%) and t(8;14)(q24.1;q32) in 21/25 265 
cases (84%). Secondary cytogenetic abnormalities were observed in 58% of the cases, of which 266 
the most frequent was gain of 1q (8/26, 31%). Other recurrent secondary changes included, loss 267 
of 13q (5/26, 19%), loss of 6q (5/26, 19%), gain of 7q (4/26, 15%) and loss of 17p (3/26, 12%). 268 
All ten cases that had a normal karotype or failed in culture were positive for MYC 269 
rearrangement by FISH.  270 
 271 
EFS and OS in total cohort of patients 272 
The outcome of the COP reduction therapy with rasburicase prophylaxis and treatment of tumour 273 
lysis syndrome has been previously reported (Galardy, et al 2013a). All evaluable patients were 274 
able to receive chemoimmunotherapy after reduction and control of tumour lysis. Of the 40 275 
evaluable patients there were 4 deaths, two toxic and two due to recurrent disease at 6 months 276 
and 8 months post study enrollment, respectively. Both patients who developed recurrent disease 277 
initially achieved complete responses to chemoimmunotherapy. The median follow-up for the 36 278 
surviving patients was 3.6 years, range (1-6). The 3-year EFS/OS for all evaluable patients was 279 
90% (CI95: 76-96%) (Fig 2A).   280 
 281 
EFS and OS in CNS positive patients 282 
Details of CNS positive patients’ presentations are shown in Tables 3A and 3B. Among CNS 283 
positive BL patients (n=15) the 3-year EFS is 93% (CI95: 61-99%) (Fig 2B). Eight CNS positive 284 
BL cases had CSF blasts [WBC median 35 (range 1-1104)]. Of the 7 CNS positive patients 285 

















anuscript          




8 CNS+ Burkitt leukaemia cases, 7 (88%) had no evidence of disease with a mean of 41 months 287 
(range, 14-72 months). One CSF positive patient with initial cranial nerve palsy and BM 288 
involvement recurred with both systemic and CNS disease. 289 
 290 
Discussion 291 
This study demonstrates for the first time that rituximab can be combined safely with FAB C1 292 
systemic and intrathecal chemotherapy.  There were, however, two toxic deaths on study. The 293 
first patient’s death due to pulmonary aspergillosis and multi-organ failure was most likely 294 
related to pre-existing aspergillosis. The second death which occurred during the recovery phase 295 
after the second induction cycle was due to severe mucositis/typhlitis and sepsis and considered 296 
possibly related to rituximab therapy. Although rituximab may have contributed to additional 297 
mucosal breakdown and resultant sepsis, the patient did not receive the required leucovorin 298 
rescue following HDMTX (8 gm/m2) clearance. The 2 of 40 toxic deaths (5%) is nearly identical 299 
to the rates reported in the same population of patients treated with FAB96 C1 without rituximab 300 
(Cairo, et al 2007, Woessmann, et al 2005).  In the previous FAB/LMB 96 group C trial, 301 
there were 11 protocol deaths not directly related to disease progression (5 infectious, 3 302 
hemorrhage, 1 thrombosis and 2 other).   The incidence of grade III/IV mucositis in the 303 
previous FAB 96 high-risk study was 68% and 52% during the two induction cycles, 304 
respectively. That latter study utilized a doxorubicin infusion time of 6- 48 hours (Cairo, et al 305 
2007). For this reason, we empirically reduced the doxorubicin infusion to 30-60 minutes in the 306 
current study and with the incorporation of rituximab and carefully monitored for excess rates of 307 
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effect on the incidence of grade III/IV mucositis with an almost 50% reduction in the current trial 309 
despite the addition of targeted immunotherapy.     310 
 311 
The 3 year EFS of 93% in CNS positive patients (without cranial radiation) is encouraging 312 
and at least as efficacious as previous reports in pediatric CNS positive mature B cell 313 
leukemia/lymphoma. This pilot was not powered to compare outcomes to the previous FAB 314 
96 trial (Cairo, et al 2012, Cairo, et al 2007, Corazzelli, et al 2012, Meinhardt, et al 2010, 315 
Thomas, et al 2006, Woessmann, et al 2005). Among CNS positive patients who relapsed on 316 
the previous FAB 96 trial, 44% had isolated systemic recurrence and  11% combined CNS 317 
and systemic disease at relapse. The remaining 45% had recurrent disease in the CNS only 318 
(Cairo et al 2007). Rituximab has poor (~ 0.1%) CNS penetration when given intravenously, but 319 
may have reduced the incidence of systemic relapse (Cairo, et al 2007, Rubenstein, et al 2003).  320 
Our results in CNS positive Burkitt patients compares favorably to the results of combined 321 
aggressive chemotherapy and rituximab in adults published by multiple adult groups. Three 322 
recent reports of combination aggressive chemotherapy (including infusional high dose 323 
methotrexate and intrathecal therapy) with the addition of rituximab reported improved efficacy 324 
of therapy with the addition of rituximab compared to past historical series in adult BL and 325 
Burkitt leukaemia. This included the MD Anderson hyper-CVAD regimen, a regimen of 326 
CODOX-M/ IVAC, and a German short intensive chemotherapy regimen (Barnes, et al 2011, 327 
Intermesoli, et al 2013, Pfreundschuh, et al 2006). Rituximab led to an improved event free 328 
survival in these three adult series for the entire patient cohorts. However, the outcomes for CNS 329 
positive adult patients with BL (n= 24; all three series combined) were poor with 3 year EFS in 330 
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Pfreundschuh, et al 2006). A recent uncontrolled prospective series of low-intensity EPOCH-R, 332 
which does not include any infusional HDMTX, reported excellent efficacy in BL but of note 333 
only one patient with CNS disease was included in this report (Dunleavy, et al 2013). Other 334 
potential CNS-directed therapy such as longer acting intrathecal therapy (e.g. liposomal ara-c) or 335 
direct administration of immune therapy into the CNS may need to be studied to improve CNS 336 
outcomes in adults with BL (Corazzelli, et al 2012, Rubenstein, et al 2003).  337 
 338 
In summary, we have demonstrated that rituximab can be safely added to the modified group 339 
FAB group C1 chemotherapy backbone in children and adolescents with advanced de-novo 340 
mature B-cell BL/Burkitt leukaemia. The 3-year EFS/OS of 90% is encouraging given the 341 
patient population including ultra-high risk subgroups, such as patients with combined BM and 342 
CNS disease and complex cytogenetics.   Based on the results of this trial, an international 343 
randomized study of FAB/LMB 96 chemotherapy ± rituximab for high risk patients is 344 
currently under investigation.  345 
 346 
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Figure Legends 571 
Figure 1. Treatment Schema. Sub-pilot and Pilot Group C patients were treated with identical 572 
FAB/LMB96 C1 systemic and intrathecal chemotherapy backbones (Patte, et al 2007). Sub-pilot 573 
schema: Rituximab 375 mg/m2/dose was administered on day -2 and day 0 of 2nd Induction cycle 574 
and day 0 of both consolidation cycles (4 total doses).  Pilot schema:  Rituximab 375 mg/m2/dose 575 
was administered on day -2 and day 0 of both induction cycles and day 0 of both consolidation 576 
cycles (6 total doses) No rituximab was administered during maintenance.   577 
 578 
Figure 2. (A) EFS and OS in all patients. Probability of EFS and OS in children and 579 
adolescents with BM and/or CNS disease with de-novo mature B-NHL treated with Rituximab 580 
and FAB Group C1 Chemotherapy Pilot on COG-ANHL01P1 as determined by Kaplan-Meier 581 
method. (B) EFS in CNS positive and CNS negative patients. Probability of EFS in children 582 
and adolescents with BM and/or CNS positive and negative disease with advanced de-novo 583 
mature B-NHL treated with Rituximab and FAB Group C1 chemotherapy stratified by CNS+ vs. 584 
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      Total 
N (%) 
N   40 
Gender Male 32 (80%) 
Age, years Mean±SD years 11±5.5 
Pathologic
al diagnosis 
Burkitt 40 (100%) 
Sites of 
Disease 
BM+/CNS- 25 (62.5%) 
  BM+/CNS+ 8 (20%) 
  BM-/CNS+ 7 (17.5%) 
LDH  ≥ 2 times Upper 
Limit of Normal 
31 (77.5%) 
BM +:  Bone marrow with > 25 % blasts by morphology 
CNS+: Central nervous system involvement (See text for details);  
COG, Children’s Oncology Group 
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